Acadian Asset Management’s ADC Therapeutics ADCT Stock Holding History

Acadian Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Sell	360,251 -88,871	-20%	-$259K	﹤0.01%	1512
2026 Q1	$1.68M	Sell	449,122 -79,843	-15%	-$315K	﹤0.01%	1009
2025 Q4	$1.86M	Buy	528,965 +301,465	+133%	+$1.22M	﹤0.01%	938
2025 Q3	$906K	Buy	+227,500	New	+$717K	﹤0.01%	1081
2024 Q3	–	Sell	-16,454	Closed	-$51K	–	2052
2024 Q2	$51K	Buy	+16,454	New	+$65.4K	﹤0.01%	1603
2024 Q1	–	Sell	-144,858	Closed	-$240K	–	1546
2023 Q4	$240K	Sell	144,858 -11,190	-7%	-$10.3K	﹤0.01%	1201
2023 Q3	$138K	Buy	156,048 +134,186	+614%	+$178K	﹤0.01%	1256
2023 Q2	$45K	Buy	+21,862	New	+$49.2K	﹤0.01%	1545
2023 Q1	–	Sell	-2,695	Closed	-$10K	–	1715
2022 Q4	$10K	Buy	+2,695	New	+$10.8K	﹤0.01%	1736

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management's ADCT Position: Q2 2026 in Review

Acadian Asset Management reduced its ADC Therapeutics (ADCT) stake by 20% in Q2 2026, selling an estimated $259K and leaving 360,251 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

Acadian Asset Management first reported a position in ADCT in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.86M in Q4 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

Acadian Asset Management held 360,251 shares of ADC Therapeutics worth $380K as of Q2 2026.
Acadian Asset Management sold 88,871 ADC Therapeutics shares in Q2 2026, an estimated $259K.
ADC Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1512 holding.
Acadian Asset Management first reported a position in ADC Therapeutics in Q4 2022 and has held it in 9 quarters since.
Acadian Asset Management's ADC Therapeutics position peaked at $1.86M in Q4 2025.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.